2 sourced · 5 unconfirmedLast updated: 2026-05-17

May 2026 Biotech Catalysts to Watch

FDA decisions and clinical trial readouts expected in May 2026, each marked with what — if anything — a primary source confirms about it. FDA PDUFA dates with filing quotes live on the PDUFA calendar.

No date on this page has been confirmed against a primary source. Unsourced entries are AI-drafted from public information and can be wrong about whether an event is still upcoming; they are listed separately and show the expected window only. Verify against the FDA, the company, or ClinicalTrials.gov before acting on any of them. 2 of 7 link to the ClinicalTrials.gov record for the program behind them — the registry confirms that the program exists, not the date.

7 catalysts shown

Playing biotech catalysts with options? tastytrade was built for thisvia tastytrade · Affiliate
May 2026monthData ReadoutPhase 3RegistryImportant
BMRNBioMarin Pharmaceutical

Phase 3 CANOPY topline data for vosoritide in idiopathic short stature

Voxzogo (vosoritide) · Idiopathic short stature (ISS)

Program confirmed on ClinicalTrials.gov · 2026-09-05 · the date itself is unverified

Sponsor record: 13 of 70 late-stage studies registered by BioMarin Pharmaceutical were stopped early. Trials stop for many reasons — see the company profile for each one.

Why it matters

BioMarin tries to expand Voxzogo beyond achondroplasia into the much larger idiopathic short stature population. Approval would multiply the addressable market by 10x+ and rescue the franchise from disappointing achondroplasia uptake.

Primary endpoint is annualized growth velocity gain vs placebo. Phase 2 data was supportive. A successful readout could double the Voxzogo franchise's peak sales estimate.

AI-drafted context, not individually reviewed.

May 2026monthConferencePhase 3RegistryImportant
AZNAstraZeneca / Daiichi Sankyo

DESTINY-Breast09 Phase 3 OS update at ASCO 2026

Enhertu (trastuzumab deruxtecan) · 1L HER2+ metastatic breast cancer

Program confirmed on ClinicalTrials.gov · 2026-09-09 · the date itself is unverified

Why it matters

AZN and Daiichi present mature overall survival data for Enhertu in front-line HER2+ metastatic breast cancer at ASCO. Confirming an OS advantage over the THP regimen would entrench Enhertu as the new 1L standard of care.

Updated OS hazard ratio with longer follow-up. Even a modest OS benefit (HR <0.85) supports continued guideline adoption. Watch for cardiac and pulmonary safety updates.

AI-drafted context, not individually reviewed.

Unconfirmed watchlist

No primary source has been found for these yet. They are AI-drafted from public information, shown with the expected window rather than a day, and may already have happened or moved. Treat them as prompts to check the company's guidance, not as dates.

May 2026monthData ReadoutPhase 3UnconfirmedMust watch
LLYEli Lilly

Phase 3 ATTAIN-1 topline data for orforglipron in obesity

Orforglipron · Obesity

Unverified — date is AI-generated and has not been checked against a primary source.

Sponsor record: 93 of 1073 late-stage studies registered by Eli Lilly were stopped early. Trials stop for many reasons — see the company profile for each one.

Why it matters

First Phase 3 readout for Lilly's once-daily oral GLP-1, orforglipron. If it delivers meaningful weight loss without GI side effects worse than injectables, this becomes a $20B+ franchise and reshapes the obesity market overnight.

Phase 2 showed ~14.7% weight loss at 36 weeks. Phase 3 needs to confirm at 72 weeks while keeping discontinuation rates below 15%. Strong data sends LLY up 5-10%; weak data triggers competitive re-rating in Viking (VKTX), Structure (GPCR), and Terns (TERN).

AI-drafted context, not individually reviewed.

May 2026monthData ReadoutPhase 3UnconfirmedMust watch
SMMTAkeso/Summit Therapeutics

HARMONi-6 Phase 3 topline data for ivonescimab in 1L PD-L1+ NSCLC

Ivonescimab · First-line PD-L1+ non-small cell lung cancer

Unverified — date is AI-generated and has not been checked against a primary source.

Why it matters

Summit's PD-1xVEGF bispecific antibody faces its definitive Phase 3 readout in the first-line lung cancer setting versus Keytruda. The 2024 HARMONi-2 study suggested ivonescimab could beat Keytruda in PD-L1+ patients. HARMONi-6 is the global confirmation.

Statistically significant PFS benefit over Keytruda would be a paradigm shift in immuno-oncology and put SMMT on a $30B+ revenue trajectory. A miss or wash sends the stock down 40-60% and resets the entire PD-1xVEGF bispecific thesis.

AI-drafted context, not individually reviewed.

May 2026monthData ReadoutPhase 3UnconfirmedImportant
GERNGeron Corporation

IMpactMF Phase 3 interim analysis for imetelstat in myelofibrosis

Rytelo (imetelstat) · JAK-inhibitor relapsed/refractory myelofibrosis

Unverified — date is AI-generated and has not been checked against a primary source.

Why it matters

Geron's first telomerase inhibitor is already approved in MDS. IMpactMF tests whether imetelstat can extend overall survival in myelofibrosis after JAK inhibitor failure — a setting with no approved options.

Survival hazard ratio below 0.7 would support an sNDA filing and approximately double the commercial opportunity for Rytelo. A wash would cap the asset at its current MDS-only ceiling.

AI-drafted context, not individually reviewed.

May 2026monthData ReadoutPhase 3UnconfirmedMust watch
REPLReplimune Group

Phase 3 IGNYTE-3 Phase 3 topline data in PD-1 failed melanoma

RP1 (vusolimogene oncorepvec) · Anti-PD-1 failed advanced melanoma

Unverified — date is AI-generated and has not been checked against a primary source.

Why it matters

Replimune's oncolytic virus immunotherapy RP1 faces its definitive Phase 3 readout following the 2025 FDA CRL. A statistically robust ORR and DOR in the post-PD-1 melanoma setting clears the path back to FDA submission.

Phase 2 data showed 32-33% objective response rate. Phase 3 needs to confirm at least a 25% ORR with durable responses. Success doubles or triples REPL; failure caps the stock indefinitely.

AI-drafted context, not individually reviewed.

May 2026monthConferencePhase 2UnconfirmedImportant
IOVAIovance Biotherapeutics

Amtagvi label expansion data update at ASCO 2026

Amtagvi (lifileucel) · Anti-PD-1 failed advanced melanoma; expansion into NSCLC

Unverified — date is AI-generated and has not been checked against a primary source.

Sponsor record: 3 of 13 late-stage studies registered by Iovance Biotherapeutics were stopped early. Trials stop for many reasons — see the company profile for each one.

Why it matters

Iovance presents updated TIL therapy data including the first meaningful Phase 2 NSCLC dataset. NSCLC expansion is critical to scaling TIL beyond a melanoma niche.

Watch for response rate, durability, and manufacturing success rate in NSCLC. A confirmed response rate above 20% with manageable safety would meaningfully expand IOVA's TAM.

AI-drafted context, not individually reviewed.

Market context

May 2026 is the heaviest catalyst month of the first half, anchored by the ASCO Annual Meeting in Chicago (May 29 - June 2). The XBI biotech index enters the month at year-to-date highs after a strong stretch of large-cap M&A and successful Phase 3 readouts. Macro tailwinds include the Fed's first 2026 rate cut and continued capital flow back into pre-revenue biotech. The obesity and oncology subsectors dominate the catalyst slate: orforglipron's Phase 3 readout is the single most-watched event in the global GLP-1 race, while ASCO 2026 will feature pivotal updates from Enhertu, Amtagvi, and multiple ADC and bispecific programs. Gene therapy faces another defining month with the Sarepta LGMD2E PDUFA, which the market will read as a referendum on FDA's continued tolerance for AAV gene therapy after the Elevidys saga. Expect outsized stock moves: small/mid-cap names like SMMT, REPL, and GERN have binary readouts that could swing 50-100%. PDUFA-driven names (MDGL, VRTX, SRPT) and large-cap LLY rounds out a month where investors who track the catalyst calendar can meaningfully outperform.

ASCO 2026 dominates immuno-oncology and ADC narrativesOral GLP-1 race kicks off with Lilly orforglipron Phase 3FDA referendum on AAV gene therapy via Sarepta LGMD2EPD-1xVEGF bispecific paradigm tested with HARMONi-6 global readoutNon-opioid pain franchise hinges on Vertex Journavx chronic indicationMASH market reshape with Madrigal label expansion vs incoming GLP-1 entrants

Conferences this period

ASCO Annual Meeting 2026

May 29 - June 2, 2026

DESTINY-Breast09 OS updateAmtagvi NSCLC Phase 2 dataHARMONi-6 ivonescimab vs KeytrudaMultiple ADC and bispecific updatesTIGIT and LAG-3 combination data

ATS International Conference 2026

May 15-20, 2026

IPF and pulmonary fibrosis pipeline updatesSevere asthma biologics readoutsCystic fibrosis next-gen modulators

Sponsored

Trade upcoming biotech catalysts commission-free on Webull

Affiliate link — we may earn a commission at no cost to you

Want one of these readouts explained in writing?

Name a catalyst from this calendar and get a written breakdown of what the trial actually measures, what success and failure look like, and where the endpoint, safety, and financing risk sits — in 3 business days, for $249.

Get the free May 2026 catalyst briefing

Receive the next weekly briefing with the biggest upcoming catalysts, date changes, and plain-English context.

Free weekly biotech briefing. No spam. We only use this address for the briefing. By subscribing, you agree to our Privacy Policy and Terms.

No financial advice. Educational research only. Affiliate links may earn compensation.

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.